Results from the Phase 3 CheckMate-227 study showed treatment with the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) in first-line advanced non-small cell lung cancer (NSCLC) significantly increased the progression-free survival rate compared to chemo (43% vs. 13%) in patients with high tumor mutational burden (TMB).
The overall response rate in the O/Y group was 45.3% compared to 26.9% for chemo. Overall survival, although preliminary, was also favorably impacted by the O/Y combination.
Merck's data showed the efficacy of KEYTRUDA + chemo regardless of PD-1 status TMB burden.
Source : https://seekingalpha.com/news/3345795-bristol-myers-opdivo-yervoy-combo-beats-chemo-first-line-lung-cancer-shares-5-percent-merck172